Although drug users are at risk for hepatitis C virus (HCV) infection, many clients in drug treatment programs remain uninformed about their HCV serostatus. Consistent with established Human immunodeficiency virus (HIV) testing and counseling guidelines, recommendations for HCV testing procedures include the delivery of prevention messages targeting all high-risk clients. However, little research has determined whether HCV testing in these programs is accompanied by counseling for HCV antibody negative clients. In this article, we examine staff and client perceptions of pre-test and post-test counseling services at five drug treatment programs in the U.S. Some clients were dissatisfied with pre-test counseling at their programs and some HCV antibody negative clients indicated that they received minimal post-test counseling. Other participants reported that their programs did not offer any post-test counseling for HCV antibody negative clients. Gaps in the pre-test and post-test counseling services at drug treatment programs represent missed opportunities to communicate primary prevention messages to uninfected clients.
AlterM., Kruszon-MoranD., NainanO., McQuillanG., GaoF., MoyerL., KaslowR. & MargolisH. (1999). “The prevalence of hepatitis C virus infection in the United States, 1988–1994,”New England Journal of Medicine341 (8):556–562.
2.
AlterM. & MoyerL. (1998). “The importance of preventing hepatitis C virus infection among injection drug users in the United States,”Journal of Acquired Immune Deficiency Syndrome Human Retrovirology18 (Supplement 1):S6–S10.
3.
BestD., NobleA, FinchE., GossopM., SidwellC. & StrangJ. (1999). “Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment,”British Medical Journal319:290–291.
4.
Centers for Disease Control and Prevention (1998). “Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease,”Morbidity and Mortality Weekly Report47(RR-19):1–39.
5.
Centers for Disease Control and Prevention (2001). “Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women,”Morbidity and Mortality Weekly Report50(No. RR-19):1–53.
Centers for Disease Control and Prevention (August, 2005). “National hepatitis C prevention strategy: implementation of the national hepatitis C prevention strategy.” (Available at the CDC Viral Hepatitis website: www.cdc.gov/ncidod/diseases/hepatitis/c/plan/Implement.htm)
8.
ChitwoodD, McBrideD., FrenchM. & ComerfordM. (1999). “Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users and nonusers,”Substance Use & Misuse34(4&5):727–746.
9.
ContoreggiC., RexroadV. & LangeW. (1998). “Current management of infectious complications in the injecting drug user,”Journal of Substance Abuse Treatment15(2):95–106.
10.
CraineN., WalkerM., CarnwathT. & KleeH. (2004). “Hepatitis C testing and injecting risk behaviour: the results of a UK based pilot study,”International Journal of Drug Policy15:115–122.
11.
DavisM. & RhodesT. (2004). “Beyond prevention? Injecting drug user narratives about hepatitis C,”International Journal of Drug Policy15:123–131.
12.
DesJarlaisD. & SchuchatA. (2001). “Hepatitis C among drug users: déjà vu all over again?,”American Journal of Public Health91(1):21–22.
13.
DhopeshV., TaylorK. & BurkeW. (2000). “Survey of hepatitis B and C in addiction treatment unit,“American Journal of Drug and Alcohol Abuse26(4):703–707.
14.
EdlinB. (2002). “Prevention and Treatment of Hepatitis C in Injection Drug Users,”Hepatology36(5)(Supplement 1):S210–S219.
15.
EdlinB. (2004). “Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room,”International Journal of Drug Policy15:81–91.
16.
GarfeinR., VlahovD., GalaiN., DohertyM. & NelsonK. (1996). “Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses,”American Journal of Public Health86(5):655–661.
17.
HaganH., ThiedeH., WeissN., HopkinsS., DuchinJ. & AlexanderE. R. (2001). “Sharing of drug preparation equipment as a risk factor for hepatitis C,”American Journal of Public Health91(1):42–46.
18.
HeimerR., ClairS., GrauL., BluthenthalR., MarshallP. & SingerM. (2002). “Hepatitis-associated knowledge is low and the risks are high among HIV-aware injection drug users in three US cities,”Addict ion97:1277–1287.
19.
KwiatkowskiC., CorsiK. & BoothR. (2002). “The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users,”Addiction97:1289–1294.
20.
LiangT. J., RehermannB., SeeffL. & HoofnagleJ. (2000). “Pathogenesis, natural history, treatment, and prevention of hepatitis C,”Annals of Internal Medicine132(4):296–305.
21.
National Institutes of Health. (2002). “Management of hepatitis C: 2002,”NIH Consensus and State-of-the-Science Statements19(3): 1–46. (Available from http://consensus.nih.gov).
22.
PattonM. (1990). Qualitative Evaluation and Research Methods,Newbury Park: Sage Publications.
23.
RhodesT., DavisM. & JuddA. (2004) “Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty,”Addiction99: 621–633.
24.
RosenblumA., NuttbrockL., McQuistionH., MaguraS. & JosephH. (2001). “Hepatitis C and substance use in a sample of homeless people in New York City,”Journal of Addictive Diseases20(4): 15–25.
25.
SorensenJ., MassonC. & PerlmanD. (2002). “HIV/Hepatitis prevention in drug abuse treatment programs: guidance from research,”Science & PracticePerspectives (July):4–12.
26.
SteinM., MaksadJ. & ClarkeJ. (2001). “Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment,”Drug and Alcohol Dependence61:211–215.
27.
StraussS., FalkinG., VassilevZ., DesJarlaisD. & AstoneJ. (2002). “A nationwide survey of hepatitis C services provided by drug treatment programs,”Journal of Substance Abuse Treatment22:55–62.
28.
StraussS., AstoneJ., DesJarlaisD. & HaganH. (2004). “A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States,”Drug and Alcohol Dependence73:227–236.
TortuS., NeaigusA., McMahonJ. & HagaD. (2001). “Hepatitis C among non-injecting drug users: a report.”Substance Use and Misuse36:523–534.
31.
U.S. Preventive Services Task Force. (2004). “Screening for hepatitis C virus infection in adults: recommendation statement,”Annals of Internal Medicine,140(6):462–464.
32.
WengerN., LinnL., EpsteinM. & ShapiroM. (1991). “Reduction of high-risk sexual behavior among heterosexuals undergoing HIV antibody testing: a randomized clinical trial,”American Journal of Public Health81(12): 1580–1585.
33.
WinstockA., SheridanJ., LovellS., FarrellM. & StrangJ. (2002). “National survey of hepatitis testing and vaccination services provided by drug services in England and Wales,”European Journal of Clinical Microbiology & Infectious Diseases19:823–828.
34.
World Health Organization (2000). “Hepatitis C: global prevalence,”Weekly Epidemiological Record3: 18–19.
